Definium Therapeutics (DFTX) Income towards Parent Company (2021 - 2026)

Definium Therapeutics (DFTX) has reported Income towards Parent Company for 6 consecutive years, with -$58.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 191821.42% year-over-year to -$58.2 billion; the TTM figure through Mar 2026 stood at -$60.9 billion (down 58428.33% YoY), while the FY2025 annual figure was -$31.1 billion, down 632.56% from the prior year.
• Income towards Parent Company declined to -$58.2 billion in Q1 2026 per DFTX's latest filing, from -$45.2 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$5.1 million in Q4 2022 and bottomed at -$58.2 billion in Q1 2026.
• Historically, Income towards Parent Company has averaged -$3.6 billion across 5 years, with a median of -$22.0 million in 2024.
• Annual changes were most pronounced in 2022 — Income towards Parent Company surged 62.53% — and 2026, when it slumped 191821.42%.
• Definium Therapeutics' Income towards Parent Company stood at -$5.1 million in 2022, then slumped by 322.88% to -$21.7 million in 2023, then tumbled by 37.63% to -$29.8 million in 2024, then sank by 51.52% to -$45.2 million in 2025, then sank by 128642.85% to -$58.2 billion in 2026.
• Business Quant data shows DFTX's Income towards Parent Company at -$58.2 billion in Q1 2026, -$45.2 million in Q4 2025, and -$44.7 million in Q3 2025.